Oncolytics Biotech Begins New Study for Advanced Pancreatic Cancer Treatment
Oncolytics Biotech Begins New Study for Advanced Pancreatic Cancer Treatment
SAN DIEGO, and CALGARY, AB, June 20, 2024 /PRNewswire/ -- Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), a leading clinical-stage company specializing in immunotherapeutics for oncology, announced the dosing of the first patient in the new GOBLET study cohort evaluating pelareorep and modified FOLFIRINOX (mFOLFIRINOX) with or without atezolizumab (Tecentriq) in newly diagnosed metastatic pancreatic ductal adenocarcinoma (PDAC) patients. The co-primary endpoints of the cohort are objective response rate (ORR) and safety. It is supported by the US$5M Pancreatic Cancer Action Network (PanCAN) Therapeutic Accelerator Award, an innovative program established to accelerate the development of new treatments for pancreatic cancer patients. It will be conducted in collaboration with AIO-Studien-gGmbH (AIO), a clinical trial group within the German Cancer Society, as part of GOBLET, a Phase 1/2 multiple indication study evaluating pelareorep-based combinations in gastrointestinal cancers.
圣地亚哥和艾伯塔省卡尔加里，2024年6月20日 /PRNewswire/ — 专门从事肿瘤免疫疗法的领先临床阶段公司Oncolytics Biotech Inc.（纳斯达克股票代码：ONCY）（多伦多证券交易所股票代码：ONC）宣布在评估培拉瑞普和改性FOLFIRINOX（mfolfirinox）的新GOBLET研究队列中为首位患者注射剂量阿替珠单抗（Tecentriq）用于新诊断的转移性胰腺导管腺癌（PDAC）患者。该队列的共同主要终点是客观反应率（ORR）和安全性。它得到了价值500万美元的胰腺癌行动网络（PanCan）治疗加速器奖的支持，该创新计划旨在加速胰腺癌患者新疗法的开发。它将与德国癌症协会的临床试验组织AIO-Studien-GGMBH（AIO）合作进行，是GOBLET的一部分，GOBLET是一项评估胃肠道癌中基于pelareorep的组合疗法的1/2期多适应症研究。